Dr. Kavita Haribhau Kadu is a chemical technologist with a bachelor’s degree from the Institute of Chemical Technology, Mumbai. Following her undergraduate studies, she embarked on a research journey as a Junior Research Fellow at BITS Pilani – K. K. Birla Goa campus. She pursued her Ph.D. from BITS Pilani – K. K. Birla Goa campus on the synthesis and characterization of hydroxyapatite nanoparticles and investigation of their interaction with biomolecules.
Transitioning to the TNBC Precision Medicine Research Group at Tata Memorial Centre Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Dr. Kadu delved into studying the short-term chemotherapy effect on the expression of the GPX4 gene on triple-negative breast cancer subtypes. She showcased her research acumen by securing the Lalit Memorial award at the 18th National Research Scholars Meet held in ACTREC. Throughout her research journey, she demonstrated a commitment to scholarly dissemination, publishing eight papers and actively participating in conferences.
As a Fulbright-Nehru Postdoctoral Research fellow at the University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Kadu is developing Aptamer-siRNA Chimera as a novel targeted therapy for pediatric medulloblastoma. Investigating the roles of AXL and interferons, she aims to contribute significantly to understanding and treating this aggressive brain tumor. With interdisciplinary expertise and a passion for impactful research, Dr. Kadu is set to make substantial contributions to cancer biology and precision medicine, shaping the future of innovative therapeutic interventions.